Mr. Jason Birmingham reports

NOVERIS PROVIDES ANNOUNCES TRADING HALT ORDER, AND CLARIFICATION AS TO ARTICLE

The British Columbia Securities Commission (BCSC) has issued an order dated March 25, 2026, under Section 89(1) of the Securities Act (British Columbia), halting all trading in Noveris Health Sciences Inc.'s securities until April 16, 2026, due to, among other matters, unexplained and unusual fluctuations in the volume of trading in, or market price, of the company's shares traded on the Canadian Securities Exchange. The full text of the order can be viewed on SEDAR+.

The company also wishes to clarify that the company has not authorized, commissioned, or otherwise been involved in the creation or distribution of, an article concerning the company circulated by John Michaels on March 19, 2026. The company further confirms that neither the company nor its investor relations service provider was aware of the article prior to its publication, and neither has any relationship or affiliation with the individual or entities responsible for its authorship or dissemination. The company did not provide information, commentary, review, approval or input of any kind. Any statements, claims or opinions expressed in the article should not be construed as having been reviewed, verified, endorsed or supported by the company. In particular, the article states that "the company is FDA-registered." To the extent that FDA refers to U.S. Food and Drug Administration, this statement is inaccurate. The company does not have any registrations with the U.S. Food and Drug Administration, nor is actively pursuing any applications for registration for any of its products at this time. The company refers readers to its public disclosure, which remains current, and confirms that it has no material undisclosed information at this time.

Noveris intends to co-operate fully with the BCSC and to work diligently toward satisfying any conditions necessary for the resumption of trading of its common shares on the CSE. The company will provide further information as it becomes available.

About Noveris Health Sciences Inc.

The company is a biotechnology company developing the next generation of innovative medications and therapies to address mental health disorders such as nicotine addiction and posttraumatic stress disorder (PTSD). The core strategy blends advanced technology with an elaborate infrastructure for drug discovery and development. Noveris's dedicated multinational team constantly develops new paths for breakthrough treatment solutions in areas with considerable unmet needs. By collaborating with some of the world's leading specialists, the company aspires to responsibly speed up the development of breakthrough medications to provide patients with safer and more effective treatment solutions. At the same time, Noveris's approach focuses on the next generation of psychedelic medicine by creating innovative compounds with unmatched therapeutic potential through its clinical trial efforts with world-class scientific and regulatory expertise.